Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07IRF
|
|||
| Former ID |
DAP001548
|
|||
| Drug Name |
Prasugrel
|
|||
| Synonyms |
Effient (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute coronary syndrome [ICD-11: BA41; ICD-9: 411.1] | Approved | [1], [2] | |
| Company |
Lilly; Daiichi Sankyo
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H20FNO3S
|
|||
| Canonical SMILES |
CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
|
|||
| InChI |
1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
|
|||
| InChIKey |
DTGLZDAWLRGWQN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 150322-43-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12015290, 14755496, 17194902, 43529826, 50546070, 57371939, 92718874, 92729702, 93581167, 99007939, 99246149, 99437235, 99443238, 114788002, 118844214, 124757123, 124772077, 124899264, 125003151, 125163927, 125341579, 126621261, 126647919, 126667058, 127783798, 131299795, 134357981, 135262112, 136023837, 136948147, 137234076, 140025693, 143497952, 144155824, 151980606, 152237337, 152258668, 152344171, 160647505, 160682499, 160967853, 162189604, 163772054, 164823943, 164830144, 165237612, 166232249, 170501032, 172085106, 172089108
|
|||
| ChEBI ID |
CHEBI:87723
|
|||
| ADReCS Drug ID | BADD_D01822 ; BADD_D01823 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Experimental Method | High-throughput screening | |||
| Description | Prasugrel can be metabolized by gut microbiota. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2Y purinoceptor 12 (P2RY12) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Platelet activation | |||
| Reactome | P2Y receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7562). | |||
| REF 2 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | |||
| REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.